Parent Project Muscular Dystrophy: Home

Parent Project Muscular Dystrophy: Home: "Once again, TRND is accepting proposals, due April 26, 2011. This program is part of a congressionally mandated program to encourage and speed the development of new drugs for rare and neglected diseases. This unique program creates a drug development pipeline within the NIH and is specifically intended to stimulate research collaborations with academic scientists, non-profit organizations, and pharmaceutical and biotechnology companies working on rare and neglected illnesses."

£2.5m research grant for Duchenne Muscular Dystrophy awarded to Oxford researchers - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

£2.5m research grant for Duchenne Muscular Dystrophy awarded to Oxford researchers - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "£2.5M RESEARCH GRANT FOR DUCHENNE MUSCULAR DYSTROPHY AWARDED TO OXFORD RESEARCHERS
Funding for pioneering research into gene therapy by Action Duchenne has led to further funds for research into this life limiting disease"

Action Duchenne welcomes backtrack on NHS plans - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

Action Duchenne welcomes backtrack on NHS plans - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "ACTION DUCHENNE WELCOMES BACKTRACK ON NHS PLANS
Charity states that government plans that threaten the most vulnerable must now be re-examined, young men to lobby parliament for access to treatment"

Phrixus Pharmaceuticals, Inc. Announces $890,000 in NIH Funding for Its Programs in Duchenne Muscular Dystrophy and Heart Failure

Phrixus Pharmaceuticals, Inc. Announces $890,000 in NIH Funding for Its Programs in Duchenne Muscular Dystrophy and Heart Failure: "Phrixus Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on innovative therapies for Duchenne muscular dystrophy (DMD) and heart failure, today announced that it has received a total of $890,000 in awards from the National Institutes of Health (NIH). Funding is in the form of one SBIR Phase 1 award titled 'Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the mdx Mouse' and one STTR Phase 1 award titled 'Poloxamer 188 Mechanism of Action in Ischemic Heart Failure.' The latter award is in collaboration with Dr. Joseph M. Metzger, Chair of Integrative Biology and Physiology at the University of Minnesota."

Cedars-Sinai receives $750,000 grant from Parent Project Muscular Dystrophy for sildenafil/taladafil study

Cedars-Sinai receives $750,000 grant from Parent Project Muscular Dystrophy for sildenafil/taladafil study: "Cedars-Sinai receives $750,000 grant from Parent Project Muscular Dystrophy for sildenafil/taladafil study"

Parent Project Muscular Dystrophy: Cialis® (Tadalafil)

Parent Project Muscular Dystrophy: Cialis® (Tadalafil): "In Duchenne (and some cases of Becker) the lack of dystrophin causes, among other things, a decrease in nitric oxide, which normally stimulates cGMP and holds blood vessels open during muscle contraction. Without adequate NO levels, it is thought that the muscles of those with Duchenne and Becker may experience “ischemia,” or damage due to a lack of oxygen. By blocking PDE-5, tadalafil may be able to compensate for the loss of NO at the muscle membrane by upregulating cGMP directly and protecting the muscles of those with Duchenne/Becker during exercise."

Google Reader (10)

Google Reader (10): "Mitch Sevier, a talented photographer and father of a son with Duchenne, has put together some incredible images that we feel truly capture what Duchenne “looks” like. These photographs illustrate Duchenne in a way PPMD has never experienced."